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Results: Comparing with the control group and sham-
operated group, inﬂammation occurred and collagen
content increased, the expression of IGFBPrP1, Collagen
III, p-Smad2/3, Smad3 increased in liver tissue of Operation
group (P < 0.01). While the differences of those in lung
tissue were not signiﬁcant (P < 0.05). More TUNEL positive
cells were found in operative group than normal group and
sham-operated group (P < 0.01).
Conclusion: Exogenous IGFBPrP1 released at a continuous
constant dose may induce hepatic ﬁbrosis of mice. On the
same condition, the effect of IGFBPrP1 on mice lung tissue
was weaker than that on hepatic tissue and pulmonary
ﬁbrosis was not found. IGFBPrP1 maybe has a selectively
functions on mice tissue.
PP-155 The effect of exogenous IGFBPrP1 on liver and
kidney in mice
L.X. Liu1, H.Y. Zhang1 *, Q.Q. Zhang1. 1The First Hospital
of Shanxi Medical University, China
Objectives: To investigate the effect of exogenous
recombinant mouse insulin-like growth factor binding
protein related protein 1 (rmIGFBPrP1) on both liver and
kidney tissue with mouse, explore the mechanism of
rmIGFBPrP1 on ﬁbrosis.
Methods: A total of 26 clean male wild-type C57BL/6 mice
were randomly divided into normal control group, sham-
operated group and model group. We used rmIGFBPrP1
which was released by capsule osmotic pump to make the
model. HE staining and Sirius red staining were observed to
investigate the pathological changes, deposition of collagen
ﬁbers of both liver and kidney of mice. The expression and
distribution of IGFBPrP1, Smad3, p-Smad2/3, III collagen
(Collagen III) of liver and kidney tissues were detected by
immunohistochemistry. Hepatocyte apoptosis was detected
by DUTP nick end labeling (TUNEL).
Results: Comparing with the control group and sham-
operated group, the content of collagen ﬁber increased,
expression of IGFBPrP1, Smad3, p-Smad2/3, Collagen III
increased (P < 0.01) in the liver of model group. Only
the expression of IGFBPrP1 in the kidney of model group
increased than the control group and sham-operated group
(P < 0.01), there is no difference on collagen ﬁbers content
and Other indicators expression (P > 0.05). TUNEL showed an
increase in ratio of apoptotic liver cells in model group than
the normal group and sham-operated group, the difference
was statistically signiﬁcant (P < 0.01).
Conclusion: Exogenous IGFBPrP1 can promote hepatocyte
apoptosis and liver ﬁbrosis, but have little effect on the
mice kidney. IGFBPrP1 maybe has the selectivity on inducing
organs and organization ﬁbrosis of mouse.
PP-156 IGFBPrP1 siRNA induced apoptosis in rat hepatic
stellate cells and its mechanism
L.X. Liu1 *, X.H. Guo1, Q.Q. Zhang1. 1The First Hospital of
Shanxi Medical University, China
Objectives: To investigate the inﬂuence of inhibiting
insulin-like growth factor binding protein related protein1
(IGFBPrP1) by chemically synthesized small interfering RNA
(siRNA) on apoptosis of HSC-T6 cells and to explore the
possible mechanism.
Methods: Divide the HSC-T6 cells into three groups as
following: normal control group, negative control group
and IGFBPrP1 siRNA transfection group. The IGFBPrP1 siRNA
was transfected into HSC-T6 cells. After transfecting with
different time, cell proliferation was measured by CCK-8
assay, cell apoptosis was detected by ﬂow cytometry with
AnnexinV/PI double staining, both p53 and bcl-2 protein
expressions were detected by immunocytochemistry.
Results: (24 h, 48 h, 72 h) after IGFBPrP1 siRNA transfection,
the rates of proliferation inhibition were (25%, 32%, 28%);
apoptotic rates of IGFBPrP1 siRNA transfection groups
were increased compared with the normal control group
and the negative control group, respectively, (P < 0.01).
Immunocytochemistry showed that the expression of p53
protein was signiﬁcantly increased and the expression of
bcl-2 protein was signiﬁcantly decreased compared with
the normal control group and the negative control group,
respectively, (P < 0.01).
Conclusion: IGFBPrP1 siRNA is able to inhibite the cell
proliferation signiﬁcantly and induce apoptosis of HSC-T6
cells effectively. Apoptosis of HSC-T6 cells induced by
IGFBPrP1 siRNA may be associated with up-regulation of
p53 expression and down-regulation of bcl-2 expression.
RNAi against IGFBPrP1 may provide a new strategy for the
treatment of liver ﬁbrosis.
PP-157 Portal application of autologous CD133+
bone marrow cells to induce liver regeneration
in a patient with cirrhosis
Y.N. Li1 *, G.H. Han2, W.Q. Wu1, J.J. Zhou1,3, W. Bai3,
M.L. Li1. 1Depart.of Infec. Dis., The 323 Military Hospital,
2Department of Digestive Diseases, Xijing Hospital, The
Fourth Military Medical University, 3Centre for Stem cell
Research, The 323 Military Hospital, China
More and more efforts have been making in order
to trigger hepatocyte regeneration through autological
bone marrow stem cells in severe chronic liver disease
although the condition and mechanism of bone marrow
stem cell differentiation into hepatocyte remains blurred.
We report a case of compensated cirrhosis induced by
chronic hepatitis B. The patient accepted portal infusion of
autologous CD133+ mononuclear cells combined with portal
vein embolisation after granulocyt colohy-stimulatins factor
(G-CSF) mohilization, bone marrow stem cells collection
and selection.A mild ﬂare of serum bilirubin, alanine
aminotransferase, albumin, fetoproten and blood platelet
count were observed within two weeks after procedure.
The serum aspartate aminotransferase and white blood
cell count showed a temporary raise, then returned to
basis level rapidly. The most import observation is the
hepatic volumetry of segment concerned stem cells infusion
signiﬁcantly increased from 368ml to 468ml three months
later after therapy. No obvious reactions and comlications
were found in this patient. Intrahepatic infusion of bone
morrow stem cells seemed safe and associates with
enlarging hepatic functional remnant volume, a promising
approach to accelerate the repopulation of hepatocytes in
patient with cirrhosis.
PP-158 Steroid resistance: the main blockhouse in the
treatment of alcoholic hepatitis
F. Wang1 *, B.-Y. Wang1. 1Department of gastroenterology,
the First Afﬁliated Hospital of China Medical University,
China
Alcoholic hepatitis (AH) is a necrotizing inﬂammatory lesion
of alcoholic liver injury with signiﬁcant short-term mortality.
The management of AH is challenging. Corticosteroids,
demonstrated anti-inﬂammatory and antiﬁbrotic effects,
are the most intensely studied and yet most hotly debated
treatment for AH. There are more than 17 controlled
trials and at least 13 meta-analyses about corticosteroids
treatment in AH in the past 40 years. Many of them are
poorly designed and varying in inclusion/exclusion criteria,
which make it hard to reach a consensus conclusion. To
resolve this confounding, researchers in both sides of the
controversy all made Cochrane review through combining
S90 Abstracts, 5th DICID
and re-analyzing individual patient data across clinical
trials in recent years, but got opposite conclusions. In
this review, we summarize the controversial data in the
past decades and analysis the potential reasons for the
different therapeutic effects of corticosteroids in AH.
Steroid resistance, widely prevailed in AH patients, is the
paramount reason for the poor prognosis of AH patients
during steroids therapy. Early response to glucocorticoids,
determined by calculating the Lille score after 7 days
of treatment, has been shown to be a clinically useful
indicator. Moreover, the development/worsening of severe
infections, the most worrisome of complications during
corticosteroids treatment AH, has also been demonstrated
to be mainly associated with non-responsiveness rather than
corticosteroids treatment itself. Improving the impaired
steroids sensitivity, reducing the infection risk and
rationalizing the therapeutic strategy of corticosteroids in
AH patients are crucial for therapeutic effect. We need to
look beyond the traditional debate and view the use of
corticosteroids in AH from a fresh perspective.
PP-159 Application and predictive value of indocyanine
green (ICG) clearance test by pulse dye
densitometry (PDD) in patients with liver
failure
A.-R. Hu1 *, S.-W. Jiang1, J.-M. Ye1. 1Ningbo No.2 Hospital,
Ningbo Infectious Diseases Hospital, China
Objective: The aim of this study was to investigate the
efﬁcacy and the value of indocyanine green retention at
ﬁfteen minutes (ICGR15) for hepatic reserve function in
patients with liver failure by pulse dye densitometry (PDD).
Methods: Among 127 cases with liver failure, there were
3 cases with ALF, 26 cases with SALF, 58 cases with ACLF
and 40 cases with CLF. According to clinical outcome at
discharge, all patients were divided into cured restorative
group (80 cases) and untreated group (47 cases). 23 patients
with tendency to liver failure were served as control group.
The ICGR15 (the unit was %) of all 150 patients were
measured by PDD.
Results: The basic ICGR15 values were 53.31±11.22 in
patients with liver failure and 48.33±10.28 in patients with
tendency to liver failure, 48.83±10.43 in cured restorative
group and 60.95±7.95 in untreated group. The differences
were statistically signiﬁcant (t = 1.983, P = 0.049; t = 6.874,
P < 0.001). Compared to gender distribution, there was no
signiﬁcant difference with ICGR15 in patients with liver
failure, but was statistically signiﬁcant compared to age
distribution (50 years as the limit) (t = 4.254, P < 0.001). The
basic ICGR15 values were statistically signiﬁcant among the
patients with CLF, SALF and ACLF (F = 7.222, 5.394, 9.088;
P = 0.009, 0.017, 0.002), and were statistically signiﬁcant
among early stage, medium stage and end stage of liver
failure. The dynamic ICGR15 values were no signiﬁcant
difference with the basic values in cured restorative
group (t = 0.956, P = 0.341), but in untreated group were
signiﬁcantly higher than the basic values (66.97±7.01 VS
60.95±7.95; t = 3.891, P < 0.001). The changes of dynamic
ICGR15 values were mainly rising in untreated group (86.42%)
(c2 = 59.349, P < 0.001). The areas under the ROC curve
(AUC) of PT, CTP, MELD, basic ICGR15 values and dynamic
ICGR15 values to predict the prognosis of liver failure were
0.823, 0.711, 0.862, 0.824 and 0.960.
Conclusion: If the indocyanine green clearance test is used
in patients with liver failure, the values of ICGR15 will be
a good indicator to evaluate the patients’ liver function,
disease severity and prognosis.
PP-160 Lamivudine treatment is associated with
improved survival in fulminant hepatitis B
J.-W. Yu1 *, L.-J. Sun1. 1Department of Infectious Diseases,
Second Afﬁliated Hospital, Harbin Medical University,
China
To evaluate the efﬁcacy of lamivudine in patients with
fulminant hepatitis B and study the prognostic factors.
Methods: A matched retrospective cohort study using
data on fulminant hepatitis B patients derived from our
hospital database was conducted. Forty patients receiving
lamivudine treatment were selected into the lamivudine
treatment group with another 40 without lamivudine
treatment studied as control. The mortality of patients
in two groups was compared. The inﬂuential factors on the
mortality were studied by Cox proportional hazards model.
Results: The mortality of patients in the lamivudine group
(n = 38) was signiﬁcantly lower than that of control group
(n = 39) (63.2% vs. 84.6%; X2 = 4.609, P = 0.032). For patients
without SIRS, the mortality of patients in the lamivudine
group (n = 25) was signiﬁcantly lower than that of control
group (n = 26) (52.0% vs. 80.8%; X2 = 4.747, P = 0.029). In
multivariate Cox proportional hazards analyses, for patients
without SIRS, age (P = 0.037), ratio of total to direct bilirubin
(P = 0.008), treatment method (P = 0.005) and the decline of
HBV DNA load during therapy (P = 0.019) were independent
predictors of prognosis.
Conclusions: Treatment with lamivudine signiﬁcantly
decreases the mortality of fulminant hepatitis B patients
without SIRS, and a rapid decline of HBV DNA load is one of
good predictors for the treatment outcome.
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PP-161 Cryptococcus meningitis in an AIDS patient
exacerbated by corticosteroids: a case report
Z.L. Hu1 *, H.X. Wei1, W.H. Yao1, C. Chen1, Y.F. Yang1. 1The
Second afﬁliated Hospital of South-East University, China
Introduction: Cryptococcus meningitis (CM) is a common
cause of mortality in advanced HIV infected patients. Use
of corticosteroid and immunosuppressive drugs can also
make a person more susceptible to CM.
Case Description: We report the case of a 35-year-old
male with CM that was exacerbated by corticosteroids.
The patient complained fever and headache 1 week
after commencing HAART. He was misdiagnosis with
viral meningitis which was coincidently relieved by
ﬂuconazole therapy for oral candidiasis. His headache
reoccurred after 38 days during which we produced
ﬁve lumbar punctures that showed relatively normal CSF
biochemistry and pressure ﬁnding. India ink preparation,
alcian blue stain and CSF/blood culture couldn’t conﬁrm a
CM. Diagnostic anti-tuberculosis treatment was initiated
in combination with 10mg/day dexamethasone. Fever
reappearanced 3 days later. Immune reconstitution
inﬂammatory syndrome was suspected and the patient was
received 160mg/per meprednisone for two days. Fever
and headache exacerbated and seizure occurred. Lumbar
punture showed elevated CSF open pressure (620mmH2O),
worsed routine biochemical test and positive culture and
stain for Cryptococcus neoformans. His disease quickly
progressed with serious hearing/vision impairment and
frequent onset of seizure and coma although steroids were
withdrawn and antifungal therapy initiated.
Corticosteroids should be used cautiously when CM couldn’t
be excluded.
